Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
阿里拉姆制药股价下跌。该公司宣布了其HELIOS-b第3期研究药物Vutrisiran的结果，该药物是一种用于治疗具有心肌病的ATTR淀粉样变性的RNAi疗法。
Alnylam Pharmaceuticals Shares Are Trading Lower. The Company Announced Results From Its HELIOS-B Phase 3 Study of Vutrisiran, an Investigational RNAi Therapeutic in Development for the Treatment of ATTR Amyloidosis With Cardiomyopathy.
阿里拉姆制药股价下跌。该公司宣布了其HELIOS-b第3期研究药物Vutrisiran的结果，该药物是一种用于治疗具有心肌病的ATTR淀粉样变性的RNAi疗法。